Company intelligence / Profile preview

Revalia Bio

West Haven, Connecticut, United Statesrevaliabio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Revalia Bio has developed a proprietary platform that uses perfused, donated human organs unsuitable for transplantation as ex vivo models to accelerate drug discovery and validation. This approach allows for rapid generation of clinically relevant data without risk to living patients, enabling "Phase 0" trials directly on real human tissue. The company is still at the seed stage with no reported clinical trial results yet.

Therapeutic areas: Nephrology
Modalities: Ex vivo human organ modelsPotentially biologics (based on referenced research)
Industry: Drug Discovery Services

Partnerships

National Kidney Foundation Innovation Fund investment/collaboration

Beyond the preview

Go deeper on Revalia Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revalia Bio.

Explore the full profile